Warfarin is the standard of care, and direct oral anticoagulants (DOACs) are a group of
newer drugs to prevent stroke in patients with valvular heart disease. The aim of this meta …

Purpose: There is uncertainty as to which anticoagulant should be used in non-valvular
atrial fibrillation (AF) with valvular heart disease. This systematic review and meta-analysis …

Background: Both valvular heart disease (VHD) and atrial fibrillation (AF) frequently coexist.
AF is an important cause of arrhythmias with a definitive cardiovascular morbidity. The use of …

Background: Direct oral anticoagulants (DOACS) are approved for use in non-valvular atrial
fibrillation (AF). This systematic review and meta-analysis aimed to evaluate the efficacy and …

Direct oral anticoagulants (DOACs) are indicated by the European Medicines Agency and
US Food and Drug Administration for stroke prevention in patients with nonvalvular atrial …

Atrial fibrillation patients with concomitant valvulopathies constitute a group with high
thromboembolic risk and should be treated with oral anticoagulation. There is good …

Direct oral anticoagulants (DOACs) are indicated for stroke prevention in patients with
nonvalvular atrial fibrillation (NVAF), which, according to the American College of …

Currently, direct oral anticoagulants (DOACs) are the first-line anticoagulant strategy in
patients with non-valvular atrial fibrillation (NVAF). They are characterized by a more …

Abstract Purpose of Review To review the clinical evidence underlying the efficacy and
safety of the use of direct oral anticoagulants (DOACs) for the treatment of patients with …

Background The original non–vitamin K antagonist oral anticoagulant (NOAC) trials in
nonvalvular atrial fibrillation (AF) enrolled patients with native valve pathologies. The object …